May 18, 2020 / 8:16 AM / 20 days ago

EU's initial green-light to remdesivir might be granted in coming days - EMA

BRUSSELS, May 18 (Reuters) - The head of the European Union's medicines agency Guido Rasi said on Monday an initial authorisation for U.S. pharmaceutical company Gilead's remdesivir as a COVID-19 treatment could be granted in coming days.

"It might be that a conditional market authorisation can be issued in the coming days," Rasi told a hearing in the EU Parliament in Brussels.

The European Medicines Agency (EMA) has already recommended the compassionate use of remdesivir, which allows a drug to be administered to patients even before it has been fully authorised. (Reporting by Francesco Guarascio; Editing by Alex Richardson)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below